Spinal Modulation Completes Axium U.S. Trial Enrollment

Menlo Park, Calif.-based Spinal Modulation Inc. has completed enrollment of the Accurate study, a randomized, controlled pivotal clinical trial designed to evaluate the safety and efficacy of the company’s Axium neurostimulator system.

The Axium system is a targeted form of spinal cord stimulation (SCS), which uses an implantable medical device to deliver mild electrical pulses that mask or interrupt pain signals as they travel from the periphery to the brain. The Axium system targets the dorsal root ganglion (DRG), a neural structure within the spine that has been shown to play a critical role in the development and maintenance of chronic pain.

The Accurate study enrolled 152 patients at 22 centers throughout the United States.

“Approximately 10-50 percent of patients who undergo common procedures like hernia repair, knee surgery, and other lower limb surgeries will suffer from chronic pain resulting from nerve injury. These conditions have historically been difficult to treat with currently available technology,” said Timothy Deer, M.D., co-study lead and CEO and president of the Center for Pain Relief in Charleston, W.V. “The Accurate trial is a landmark study that could change the way we treat these chronic pain conditions. Results from prior European studies have been promising, and we are hopeful that the Accurate trial will continue to substantiate the effectiveness of this therapy for our patients.”

Investigators will present the Accurate trial design at the 18th Annual North American Neuromodulation Society (NANS) meeting in Las Vegas, Nev., held from Dec. 11–14. Clinical outcomes from Europe and Australia, where the Axium system is commercially available, will also be presented.